Full Press Release Details
GRAIL to host Capital Markets Day on May 13 , 2024
SAN DIEGO , May 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced that it has publicly filed a Form 10 registration statement with the U.S. Securities and Exchange Commission ("SEC"), in connection with its intended divestiture of GRAIL. A version of this registration statement was submitted to the SEC last December as required.
The Form 10 includes detailed information about GRAIL, including historic financial information, a description of GRAIL's business and strategy, and other legal and financial disclosures. This filing is a necessary step for a capital markets transaction; however, it is not an indication of the means by which Illumina will ultimately divest GRAIL. A copy of the Form 10 is available on the SEC website and in the Investor Info section of Illumina's website at investor.illumina.com .
"Illumina remains committed to divesting GRAIL expeditiously, and on terms consistent with our divestment plan, which was approved by the European Commission. Our goal is to finalize the divestiture terms by the end of the second quarter of 2024," said Jacob Thaysen , CEO of Illumina. "Illumina's Board and management team continue to focus on our core business, supporting our customers, and driving long-term growth."
GRAIL Capital Markets Day to take place on May 13
GRAIL will host a virtual Capital Markets Day that will begin at 7:00 am PT / 10:00 am ET on May 13, 2024 . The event will feature presentations from GRAIL leaders outlining Galleri, a clinically validated, commercially available multi-cancer early detection test, and the Company's scientific background and addressable market opportunity, business strategy, and financial profile. The event will include a live Q&A session following speaker presentations.
Interested parties may access the live teleconference here .
Transaction details
In the event of a capital markets separation, the transaction is intended to qualify as a tax-free distribution, for U.S. federal income tax purposes, to U.S. shareholders of new publicly traded stock in GRAIL. To that end, Illumina has received a favorable ruling from the IRS with respect to the tax-free nature of the transaction.
Illumina intends to finalize the terms of the divestiture in second quarter 2024 in a manner consistent with its divestment plan, which was approved by the European Commission, and subject to the satisfaction of certain conditions including, among others, final approval of Illumina's Board of Directors and the effectiveness of a Form 10 registration statement that will be filed with the U.S. Securities and Exchange Commission. There can be no assurance regarding the ultimate timing of the proposed transaction or that the transaction fund will be completed.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter) , Facebook , LinkedIn , Instagram , TikTok , and YouTube .
Illumina investors: Salli Schwartz 858-291-6421 [email protected]
Illumina media: Samantha Beal 714-227-2661 [email protected]
GRAIL investors: Alex Dobbin [email protected]
GRAIL media: Trish Rowland Kristen Davis [email protected]
SOURCE Illumina, Inc.